• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Early Indication of Androgen Deprivation Resistance

Video

Peter Salgo, MD, and Ira M. Klein, MD, MBA, FACP, discuss the treatment of prostate cancer with androgen deprivation therapy (ADT) and note that additional research is necessary to help determine which patient populations are at highest risk for developing resistance following ADT.

Dr Klein explains that after a patient receives ADT, the only indicator that providers have for detecting resistance is disease progression. Unfortunately, he adds, each patient responds differently and the time to onset of resistance is variable.

For this reason, Dr Klein emphasizes the need for additional population-based clinical studies and research on the activation of signaling pathways. Being able to categorize patients, look at specific cell surface markers, and conduct additional next-generation sequencing can help providers appropriately manage their patients, he remarks.

Watch our related Peer Exchange, Oncology Stakeholder Summit 2014: Evidence-Based Decisions to Improve Quality and Regulate Costs


Related Videos
Will Shapiro
Mila Felder, MD, FACEP
Kiana Mehring, MBA, director of strategic partnerships, managed care at Florida Cancer Specialists & Research Institute (FCS)
Miriam J. Atkins, MD, FACP, president of the Community Oncology Alliance (COA) and physician and partner of AO Multispecialty Clinic in Augusta, Georgia.
Dr Lucy Langer
Edward Arrowsmith, MD, MPH
Dr Kathi Mooney
Tiago Biachi de Castria, MD, PhD, Moffitt Cancer Center
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.